Ningbo Menovo Pharmaceutical Co.Ltd(603538) announced that Zhejiang Liaoyuan mirtazapine API, the holding subsidiary of the company, passed the technical review of the drug evaluation center of the State Drug Administration (hereinafter referred to as “CDE”), and the registration number was changed to “a” status on the CDE API, pharmaceutical excipients and drug packaging materials registration information publicity platform. The drug is suitable for the treatment of depression. It can improve depressive symptoms, sleep structure and sleep quality; Cause less sexual dysfunction and improve patient compliance; Easy to use, less drug interaction and good tolerance.
The company issued a stock trading announcement on the same day. On March 15, 2022, the company disclosed the relevant matters passed the filing of the “new project with an annual output of 60 tons of anti covid-19 drug nimatovir API and its key intermediates”. At present, the API of nimatovir studied by the company has not obtained relevant authorization and is only used for laboratory research and development. Intermediates SM1, SM2 and T13 are pharmaceutical and chemical products, without compound patents and full market competition. They are not produced exclusively by the company.
